The round was led by XTX Ventures to support expansion across health and wellbeing markets.
"The demand for alternative pathways to access mental healthcare is enormous, and continues to grow by the day. We’re committed to disrupting traditional approaches to healthcare to help improve the quality of people’s lives, and we’re particularly focused on the perinatal mental health sector. With the support of XTX Ventures, Foresight Group and Praetura Ventures, we’ll strengthen the rollout of new clinical trials and product development, and champion the benefits of technology for reinforcing healthcare provision on a national, regional and global basis."
TSP Ventures co-led the round, supported by Foresight Group, the British Business Bank, the University of Nottingham, and angel investors.
"We are delighted to be joining the Promethean Particles team and becoming a part of their onward journey. On the current trajectory, global warming is predicted to reach 2.7°C by 2100. Hitting the 1.5°C target established in the 2015 Paris Agreement will require a 45% reduction in annual global emissions by 2030. However, even with all the current climate pledges and commitments, global emissions are set to increase significantly over this period. At TSP, we believe that hitting, or even getting close to this target without carbon capture is now virtually impossible. Bringing down the cost of carbon capture (both point-source and Direct Air Capture) is essential and as Venture Capitalists, we believe it is our role to support emerging, World-changing technologies through the difficult development period to full commercialisation. Under the experienced leadership of CEO James Stephenson, we are certain that the Promethean team have all the necessary knowledge and expertise to scale this technology."
Foresight Group backed Ruleguard with a £3.5m growth equity investment to expand its software capabilities and market reach.
"Ruleguard represents a great opportunity to invest in a rapidly growing Reg Tech business with high quality recurring revenues and excellent customer feedback. The Company’s target market is large and expanding, with increasing regulatory complexity necessitating increased adoption of specialised technology. Ruleguard’s well-rounded team is well placed to drive further rapid growth, and we look forward to being part of the Company’s next growth stage."
The funding round was led by Foresight Group alongside existing investors Parkwalk Advisors and Oxford Science Enterprise.
"Opsydia’s technology has the potential to become the de facto marking standard in the diamond industry for the next 20 years. We look forward to supporting Opsydia’s experienced Management team as they deliver on this ambition."
Foresight Group led the investment round with participation from angel backers to support the expansion of the company radiology technology.
"We are very pleased to have closed this round following extraordinary levels of interest where we were oversubscribed. There has been an explosion of early stage healthtech funding across Europe, but we think that Hexarad has connected with investors because we are developing healthcare technology that truly addresses the biggest issues facing healthcare providers. Our first-hand experience of the pressure that radiology departments are under means that we are uniquely placed to develop innovative, clinically-led solutions"
